Breaking News, Promotions & Moves

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

Snellgrove brings 30+ years of financial leadership, strategic insight, and operational excellence across the biopharmaceutical and medtech sectors.

Author Image

By: Charlie Sternberg

Associate Editor

Halozyme Therapeutics Inc. has appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. Snellgrove will be responsible for leading Halozyme’s financial operations and strategy, including capital allocation, corporate development and investor relations. He will report to Helen Torley, President and Chief Executive Officer. “I am delighted to have a financial leader of Darren’s experience and caliber join Halozyme at this exciting time. He is a highly...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters